Full-Time

Associate Director

Digital Engagement and Innovation

Posted on 11/23/2025

Travere Therapeutics

Travere Therapeutics

501-1,000 employees

Develops and commercializes rare-disease therapies

Compensation Overview

$146k - $190k/yr

+ Short-term incentive + Long-term incentive (company stock)

Remote in USA

Remote

Category
IT & Security (1)
Requirements
  • Bachelor's degree in Life Sciences, Business, Digital Marketing, or related field. Advanced degree (MBA, MS, PharmD/PhD) preferred. Equivalent combination of education and applicable job experience may be considered.
  • 8 years of pharmaceutical industry experience preferably in Medical Affairs with working knowledge of digital operations or healthcare innovation
  • Proven experience in technology governance, project management, and cross-functional coordination
  • Experience with digital platforms, vendor management, and compliance in regulated environments
  • Strong understanding of pharmaceutical industry regulatory standards (GxP, compliance requirements)
  • Experience with CRM systems, digital engagement platforms, and medical technology tools
  • Excellent project management, facilitation, and stakeholder communication skills
  • Strong analytical and strategic thinking capabilities with execution focus
  • Proven ability to influence without authority and drive cross-functional collaboration
  • Experience in change management and technology adoption initiatives
  • Strong interpersonal and relationship-building skills across all organizational levels
  • Excellent written and verbal communication skills with ability to tailor messages to different audiences
  • Proficiency in Microsoft Office Suite and familiarity with data visualization tools
  • Ability to adapt to changing priorities and implement new strategies in fast-paced environment
  • Willingness/ability to travel up to 25%
  • Experience in Medical Affairs or pharmaceutical industry
  • Knowledge of AI implementation, digital health technologies, or automation solutions
  • Experience with IT governance frameworks and technology lifecycle management
  • Background in rare diseases or therapeutic area expertise
Responsibilities
  • IT Governance Committee Leadership (30%) Serve as primary Digital Innovation representative and potentially co-chair the Medical Affairs IT Governance Committee Drive technology evaluation, selection, deployment, and lifecycle management for medical digital platforms Lead vendor assessment and management processes, ensuring compliance, performance, and strategic alignment Champion digital innovation pilots and AI initiatives through governance framework Coordinate cross-functional alignment on digital strategy and project portfolio prioritization Manage budget recommendations and resource allocation for technology investments Facilitate resolution of technology issues through decision making and cross-functional coordination Ensure technology decisions support Medical Affairs mission and corporate strategic goals
  • Digital MSL Program Coordination (25%) Develop, maintain, and optimize Digital Opinion Leader (DOL) lists for digital MSL engagement Coordinate digital initiatives and provide operational support to 2 digital MSLs Synthesize insights from digital MSL reports into actionable intelligence for strategic decision-making Provide training and support on digital platforms, social listening tools, and engagement technologies Bridge field digital insights back to internal digital strategy and governance decisions Facilitate coordination between digital MSLs and therapeutic MSL teams for integrated approach Support development of KPIs and benchmarks for digital engagement quality and impact measurement
  • Innovation Scouting & Pilot Development (20%) Research and evaluate emerging digital health technologies, AI solutions, and engagement platforms Monitor industry trends and competitive landscape for potential adoption opportunities Identify pilot opportunities based on field insights and stakeholder feedback Develop comprehensive pilot proposals for governance committee review and approval Support strategic innovation initiatives with tactical research and feasibility analysis Document lessons learned and best practices from pilot implementations
  • Digital Governance & Compliance (15%) Develop, maintain, and implement digital standard operating procedures (SOPs) and compliance frameworks Support audit readiness documentation for digital platforms and AI-enabled tools Ensure regulatory alignment across digital channels in partnership with Legal, Compliance, and IT Manage platform governance, access controls, and user permissions Coordinate compliance reviews for digital content and engagement strategies Maintain documentation of digital workflows and approval processes
  • Digital Program Operations Coordination (10%) Coordinate operational aspects of digital initiatives, ensuring timelines and milestones are met Maintain documentation of digital workflows, project status and deliverables Support content calendar maintenance and pull-through of digital communications Own day-to-day management of MA digital vendors, including onboarding, performance monitoring and renewals
Desired Qualifications
  • Experience in Medical Affairs or pharmaceutical industry
  • Knowledge of AI implementation, digital health technologies, or automation solutions
  • Experience with IT governance frameworks and technology lifecycle management
  • Background in rare diseases or therapeutic area expertise

Travere Therapeutics develops and commercializes therapies for rare diseases, especially kidney and metabolic disorders. It has commercial products Thiola and Thiola EC for cystinuria and Chenodal for gallstones, with a pipeline that includes sparsentan for focal segmental glomerulosclerosis and IgA nephropathy. The company generates revenue from the sale of its products and supports patients through a dedicated patient assistance program. Its approach centers on identifying and delivering treatments for rare diseases, combining commercialization with ongoing drug development.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • FILSPARI Q1 2026 sales hit $105.2 million, up 88% year-over-year.
  • FSGS approval expands US addressable market beyond 100,000 patients.
  • Chugai submits sparsentan NDA in Japan 2026, triggering milestone payments.

What critics are saying

  • Robbins Geller investigates Travere for securities violations since January 2026.
  • Ligand claims 9% royalty on all worldwide FILSPARI sales.
  • Novartis atrasentan Phase III threatens 20-30% FILSPARI market share.

What makes Travere Therapeutics unique

  • FILSPARI is first FDA-approved therapy for FSGS in patients aged 8 and older.
  • FILSPARI leads IgAN market as most prescribed FDA-approved medicine.
  • Pegtibatinase advances as novel Phase 3 enzyme replacement for classical homocystinuria.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Wellness Program

Company Equity

Company News

Yahoo Finance
Apr 14th, 2026
Travere's FILSPARI receives FDA approval for FSGS, earns Ligand 9% royalty on sales

Ligand Pharmaceuticals' partner Travere Therapeutics has received FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS) in adult and paediatric patients aged eight and older without nephrotic syndrome. FILSPARI becomes the first and only FDA-approved medicine for FSGS, a rare kidney disorder and leading cause of kidney failure. The approval expands FILSPARI beyond IgA nephropathy, where it is already the most commonly prescribed FDA-approved medicine. Ligand is entitled to a 9% royalty on worldwide net sales. Travere estimates the addressable US population exceeds 30,000 individuals with FSGS without nephrotic syndrome. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 48% reduction in proteinuria compared to 27% for irbesartan in patients without nephrotic syndrome.

Yahoo Finance
Apr 13th, 2026
FDA fully approves FILSPARI for FSGS, first treatment for rare kidney disease affecting 30K US patients

Travere Therapeutics announced that the FDA has granted full approval for FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) who do not have nephrotic syndrome. FILSPARI is the first and only FDA-approved medicine for FSGS. The approval expands FILSPARI's addressable population to more than 100,000 patients in the US, including over 30,000 with FSGS. The drug is already the most commonly prescribed FDA-approved medicine for IgA nephropathy. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 46% reduction in proteinuria compared to 30% for irbesartan. In patients without nephrotic syndrome specifically, the reduction was 48% versus 27%. The medicine was generally well tolerated across adult and paediatric patients.

The Motley Fool
Jan 25th, 2026
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? | The Motley Fool

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

The Motley Fool
Jan 24th, 2026
Palisades Investment buys $5.3M stake in Travere Therapeutics as shares surge 51%

Palisades Investment Partners initiated a new position in Travere Therapeutics worth $5.26 million, acquiring 137,768 shares in the fourth quarter of 2025, according to an SEC filing. The stake represents 1.99% of the fund's $264.72 million in reportable US equity assets. Travere Therapeutics, a biotechnology company specialising in rare disease therapies, has seen its shares rise 50.89% over the past year to $27.87. The company's revenue surged to $164.9 million in the third quarter, driven by a 155% year-over-year increase in sales of its FILSPARI drug to $90.9 million. The timing of Palisades' investment coincided with FDA review of FILSPARI for potential expanded approval in focal segmental glomerulosclerosis treatments, suggesting confidence in the company's growth prospects.

GlobeNewswire
Jan 13th, 2026
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

TVTX ALERT: investigation launched into Travere Therapeutics, Inc., RGRD law attorneys encourage investors and potential witnesses to contact law Firm. SAN DIEGO, Jan. 13, 2026 (GLOBE NEWSWIRE) - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. THE COMPANY: Travere is a biopharmaceutical company that develops therapies for people living with rare kidney and metabolic diseases in the United States. THE INVESTIGATION: Robbins Geller is investigating whether Travere and certain of its top executives made materially false and/or misleading statements and/or omitted material information regarding Travere's business and operations. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases - more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever - $7.2 billion - in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.

INACTIVE